Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC

Introduction: Co-occurring mutations in KRAS-mutant NSCLC are associated with discrete biological properties and modulate therapeutic susceptibilities. As G12D-specific inhibitors are expected to enter the clinic, we sought to investigate the characteristics and outcomes of patients with KRAS G12D-m...

Full description

Bibliographic Details
Main Authors: Alissa J. Cooper, MD, Alona Muzikansky, MA, Jochen Lennerz, MD, PhD, Farhaana Narinesingh, M.B.B.S., Mari Mino-Kenudson, MD, Yin P. Hung, MD, PhD, Zofia Piotrowska, MD, MHS, Ibiayi Dagogo-Jack, MD, Lecia V. Sequist, MD, MPH, Justin F. Gainor, MD, Jessica J. Lin, MD, Rebecca S. Heist, MD, MPH
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small cell lung cancer
KRAS mutation
Targeted therapies
Co-mutations
Online Access:http://www.sciencedirect.com/science/article/pii/S266636432200114X

Internet

http://www.sciencedirect.com/science/article/pii/S266636432200114X

Similar Items